UHC1

  Cat. No.:  DC11751  
UHC1
Chemical Structure
1629960-95-7
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
A novel potent, non-agonist PPARγ ligand that blocks CDK5-mediated PPARγ phosphorylation, without the classical agonism.
Cas No.: 1629960-95-7
Chemical Name: 4'-((2,3-dimethyl-5-((pyridin-3-ylmethyl)carbamoyl)-1H-indol-1-yl)methyl)-[1,1'-biphenyl]-2-carboxylic acid
Synonyms: UHC-1;UHC 1
SMILES: C(C1=CC=C(CN2C3=C(C=C(C(=O)NCC4=CC=CN=C4)C=C3)C(C)=C2C)C=C1)1=CC=CC=C1C(O)=O
Formula: C31H27N3O3
M.Wt: 489.575
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:
Description: A novel potent, non-agonist PPARγ ligand that blocks CDK5-mediated PPARγ phosphorylation, without the classical agonism; binds directly to the LBD of PPARγ with IC50 of 800 nM, more potently blocks CDK5-mediated PPARγ phosphorylation at Ser-273 compared with SR-1664; effectively ameliorates the inflammatory response both in vitro and in high-fat diet-fed mice, dramatically improved insulin sensitivity without causing fluid retention and weight gain.
In Vivo:
In Vitro:
References:
Kinase Assay:
Cell Assay:
Animal Administration:
References:
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC29028 LY518674 LY518674 is a potent, selective PPARα antagonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis.
DC28684 iRucaparib-AP6 iRucaparib-AP6 is a highly efficient and specific PARP1 degrader based on Rucaparib by using the PROTAC approach. iRucaparib-AP6, a non-trapping PARP1 degrader, blocks both the catalytic activity and scaffolding effects of PARP1.
DC28242 15-Deoxy-Δ-12,14-prostaglandin J2 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM.
DC28072 Mifobate Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects.
DC9601 T0070907 T0070907 is a potent and selective PPARγ antagonist with IC50 of 1 nM; displays > 800-fold selectivity for PPARγ over PPARα and PPARδ.
DC11430 RB-394 RB394 is an orally bioavailable and dual modulator of soluble epoxide hydrolase (sEH) and PPARγ.
DC9897 Palmitoylethanolamide Palmitoylethanolamide(PEA) is an endogenous fatty acid amide and selectively activates PPAR-α in vitro with an EC50 value of 3.1±0.4 μM.
DC2076 L-165041 L-165041 is a potent PPARδ agonist (Ki = 6 nM).
DC7149 GW1929 GW1929 is a synthetic peroxisome proliferator-activated receptor-γ (PPARγ) agonist with IC50 of 6.2 nM and 13 nM for human and mouse, respectively.
DC12089 GW 6471 GW 6471 is a potent PPARα antagonist.